Regenxbio (RGNX) Tops Q4 EPS by 45c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Pre-Open Stock Movers 02/25: (ONCE) (CMTA) (QURE) Higher; (MDR) (CRON) (NBR) Lower (more...)
February 25, 2019 9:25 AM ESTPre-Open Movers
Spark Therapeutics (NASDAQ: ONCE) 120.9% HIGHER; announced today that it has entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of $114.50 per share in an all-cash transaction. This corresponds to a total equity value of approximately $4.8 billion on a fully diluted basis, inclusive of approximately $500 million of projected net cash expected at close. The per share price represents a premium of 122 percent to Sparks closing price on Feb. 22, 2019. The merger agreement has been unanimously approved by the boards of both Spark and... More
Evercore ISI Upgrades Regenxbio Inc. (RGNX) to Outperform
February 25, 2019 2:38 AM ESTEvercore ISI analyst Josh Schimmer upgraded Regenxbio Inc. (NASDAQ: RGNX) from In Line to Outperform.
For an analyst ratings summary and ratings history on Regenxbio Inc. click here. For more ratings news on Regenxbio Inc. click here.
Shares of Regenxbio Inc. closed at $46.50 yesterday.
... More